Download PDF
Semin Reprod Med 2021; 39(03/04): 102-110
DOI: 10.1055/s-0041-1729841
Review Article

Metabolomic Biomarkers in Polycystic Ovary Syndrome: A Review of the Evidence

Simon Alesi‡   *
1   Monash Centre for Health Research and Implementation (MCHRI), School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
,
Drishti Ghelani‡   *
1   Monash Centre for Health Research and Implementation (MCHRI), School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
,
Aya Mousa
1   Monash Centre for Health Research and Implementation (MCHRI), School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
› Author Affiliations Funding This work received no specific funding. A.M. is supported by a Peter Doherty Biomedical Research Fellowship provided by the National Health and Medical Research Council (NHMRC) of Australia.
› Further Information
    Permissions and Reprints

Abstract

Polycystic ovary syndrome (PCOS) is an endocrinologic condition affecting one in five women of reproductive age. PCOS is often characterized by disruptions to the menstrual cycle, development of male-pattern hair growth (hirsutism), and polycystic ovary morphology. Recently, PCOS has been linked to metabolic dysfunction, with 40 to 80% of women characterized as overweight or obese. Despite these well-known negative health effects of PCOS, 75% of sufferers remain undiagnosed. This is most likely due to the variability in symptom presentation and the lack of a definitive test for the condition. Metabolomics, which is a platform used to analyze and characterize a large number of metabolites, has recently been proposed as a potential tool for investigating the metabolic pathways that could be involved in the pathophysiology of PCOS. In doing so, novel biomarkers could be identified to improve diagnosis and treatment of PCOS. This review aims to summarize the findings of recent metabolomic studies that highlight metabolic-specific molecules which are deranged in PCOS, to identify potential biomarkers for the condition. Current limitations for metabolomic studies are discussed, as well as future directions to progress the field toward further validation and integration into clinical practice.

Keywords

polycystic ovary syndrome - metabolomics - biomarkers - metabolites

Authors' Contributions

S.A. and D.G. reviewed the literature and co-wrote the first draft. S.A. revised and edited the manuscript. A.M. conceptualized and determined the scope of the manuscript, supervised the review process, and revised and edited the manuscript. All authors meet ICMJE criteria for authorship and have approved the final version for publication.


* Equal contribution as joint first author.




Publication History

Article published online:
04 May 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (04) 1929-1935
    CrossrefPubMedGoogle Scholar
  • 2 Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health 2018; 15 (11) 15
    CrossrefPubMedGoogle Scholar
  • 3 Boyle J, Teede HJ. Polycystic ovary syndrome: an update. Reprod Health 2011
    Google Scholar
  • 4 Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev 2016; 37 (05) 467-520
    CrossrefPubMedGoogle Scholar
  • 5 Sam S. Obesity and polycystic ovary syndrome. Obes Manag 2007; 3 (02) 69-73
    CrossrefPubMedGoogle Scholar
  • 6 Kamangar F, Okhovat JP, Schmidt T. et al. Polycystic ovary syndrome: special diagnostic and therapeutic considerations for children. Pediatr Dermatol 2015; 32 (05) 571-578
    CrossrefPubMedGoogle Scholar
  • 7 Johnson CH, Gonzalez FJ. Challenges and opportunities of metabolomics. J Cell Physiol 2012; 227 (08) 2975-2981
    CrossrefPubMedGoogle Scholar
  • 8 Omabe M, Elom S, Omabe KN. Emerging metabolomics biomarkers of polycystic ovarian syndrome; targeting the master metabolic disrupters for diagnosis and treatment. Endocr Metab Immune Disord Drug Targets 2018; 18 (03) 221-229
    CrossrefPubMedGoogle Scholar
  • 9 Wilroy Jr RS, Givens JR, Wiser WL, Coleman SA, Andersen RN, Summitt RL. Hyperthecosis: an inheritable form of polycystic ovarian disease. Birth Defects Orig Artic Ser 1975; 11 (04) 81-85
    PubMedGoogle Scholar
  • 10 Govind A, Obhrai MS, Clayton RN. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 1999; 84 (01) 38-43
    CrossrefPubMedGoogle Scholar
  • 11 Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril 2016; 106 (04) 948-958
    CrossrefPubMedGoogle Scholar
  • 12 Teede HJ, Joham AE, Paul E. et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring) 2013; 21 (08) 1526-1532
    CrossrefPubMedGoogle Scholar
  • 13 Mikhael S, Punjala-Patel A, Gavrilova-Jordan L. Hypothalamic-pituitary-ovarian axis disorders impacting female fertility. Biomedicines 2019; 7 (01) 7
    CrossrefPubMedGoogle Scholar
  • 14 Tanguturi SC, Nagarakanti S. Polycystic ovary syndrome and periodontal disease: underlying links—a review. Indian J Endocrinol Metab 2018; 22 (02) 267-273
    CrossrefPubMedGoogle Scholar
  • 15 Pasquali R, Zanotti L, Fanelli F. et al. Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab 2016; 101 (05) 2013-2022
    CrossrefPubMedGoogle Scholar
  • 16 Lakkakula BV, Thangavelu M, Godla UR. Genetic variants associated with insulin signaling and glucose homeostasis in the pathogenesis of insulin resistance in polycystic ovary syndrome: a systematic review. J Assist Reprod Genet 2013; 30 (07) 883-895
    CrossrefPubMedGoogle Scholar
  • 17 Rodriguez Paris V, Bertoldo MJ. The mechanism of androgen actions in PCOS etiology. Med Sci (Basel) 2019; 7 (09) 7
    PubMedGoogle Scholar
  • 18 Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J Clin Endocrinol Metab 2006; 91 (03) 786-789
    CrossrefPubMedGoogle Scholar
  • 19 Lujan ME, Chizen DR, Pierson RA. Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies. J Obstet Gynaecol Can 2008; 30 (08) 671-679
    CrossrefPubMedGoogle Scholar
  • 20 Sanchez-Garrido MA, Tena-Sempere M. Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab 2020; 35: 100937
    CrossrefPubMedGoogle Scholar
  • 21 Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92 (03) 787-796
    CrossrefPubMedGoogle Scholar
  • 22 Bremer AA. Polycystic ovary syndrome in the pediatric population. Metab Syndr Relat Disord 2010; 8 (05) 375-394
    CrossrefPubMedGoogle Scholar
  • 23 Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol 2017; 18 (01) 83
    CrossrefPubMedGoogle Scholar
  • 24 Pinu FR, Goldansaz SA, Jaine J. Translational metabolomics: current challenges and future opportunities. Metabolites 2019; 9 (06) 9
    Google Scholar
  • 25 Ni C-M, Huang W-L, Jiang Y-M. et al. Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial. Trials 2020; 21 (01) 169
    CrossrefPubMedGoogle Scholar
  • 26 Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004; 22 (05) 245-252
    CrossrefPubMedGoogle Scholar
  • 27 Rajska A, Buszewska-Forajta M, Rachoń D, Markuszewski MJ. Metabolomic insight into polycystic ovary syndrome-an overview. Int J Mol Sci 2020; 21 (14) 21
    Google Scholar
  • 28 Segers K, Declerck S, Mangelings D, Heyden YV, Eeckhaut AV. Analytical techniques for metabolomic studies: a review. Bioanalysis 2019; 11 (24) 2297-2318
    CrossrefPubMedGoogle Scholar
  • 29 Wishart DS, Feunang YD, Marcu A. et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res 2018; 46 (D1): D608-D617
    CrossrefPubMedGoogle Scholar
  • 30 Griffin JL, Nicholls AW, Daykin CA. et al. Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments. Metabolomics 2007; 3: 179-188
    CrossrefPubMedGoogle Scholar
  • 31 Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001; 111 (08) 607-613
    CrossrefPubMedGoogle Scholar
  • 32 Yilmaz M, Biri A, Bukan N. et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20 (05) 258-263
    CrossrefPubMedGoogle Scholar
  • 33 Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61 (05) 946-951
    CrossrefPubMedGoogle Scholar
  • 34 Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54 (04) 447-453
    CrossrefPubMedGoogle Scholar
  • 35 Daghestani MH, Daghestani M, Daghistani M. et al. A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS). Lipids Health Dis 2018; 17 (01) 195
    CrossrefPubMedGoogle Scholar
  • 36 Schiffer L, Barnard L, Baranowski ES. et al. Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review. J Steroid Biochem Mol Biol 2019; 194: 105439
    CrossrefPubMedGoogle Scholar
  • 37 Askarpour M, Hadi A, Symonds ME. et al. Efficacy of l-carnitine supplementation for management of blood lipids: a systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2019; 29 (11) 1151-1167
    CrossrefPubMedGoogle Scholar
  • 38 Chang AY, Lalia AZ, Jenkins GD. et al. Combining a nontargeted and targeted metabolomics approach to identify metabolic pathways significantly altered in polycystic ovary syndrome. Metabolism 2017; 71: 52-63
    CrossrefPubMedGoogle Scholar
  • 39 Samimi M, Jamilian M, Ebrahimi FA, Rahimi M, Tajbakhsh B, Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf) 2016; 84 (06) 851-857
    CrossrefPubMedGoogle Scholar
  • 40 Jamilian H, Jamilian M, Samimi M. et al. Oral carnitine supplementation influences mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Gynecol Endocrinol 2017; 33 (06) 442-447
    CrossrefPubMedGoogle Scholar
  • 41 Escobar-Morreale HF, Samino S, Insenser M. et al. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem 2012; 58 (06) 999-1009
    CrossrefPubMedGoogle Scholar
  • 42 Niu Z, Lin N, Gu R, Sun Y, Feng Y. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization. J Clin Endocrinol Metab 2014; 99 (11) E2269-E2276
    CrossrefPubMedGoogle Scholar
  • 43 Zhang ZH, Vaziri ND, Wei F, Cheng XL, Bai X, Zhao YY. An integrated lipidomics and metabolomics reveal nephroprotective effect and biochemical mechanism of Rheum officinale in chronic renal failure. Sci Rep 2016; 6: 22151
    CrossrefPubMedGoogle Scholar
  • 44 Vonica CL, Ilie IR, Socaciu C. et al. Lipidomics biomarkers in women with polycystic ovary syndrome (PCOS) using ultra-high performance liquid chromatography-quadrupole time of flight electrospray in a positive ionization mode mass spectrometry. Scand J Clin Lab Invest 2019; 79 (06) 437-442
    CrossrefPubMedGoogle Scholar
  • 45 Ayala A, Muñoz MF, Argüelles S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014; 2014: 360438
    CrossrefPubMedGoogle Scholar
  • 46 Li J, Xie LM, Song JL. et al. Alterations of sphingolipid metabolism in different types of polycystic ovary syndrome. Sci Rep 2019; 9 (01) 3204
    CrossrefPubMedGoogle Scholar
  • 47 Moran LJ, Mundra PA, Teede HJ, Meikle PJ. The association of the lipidomic profile with features of polycystic ovary syndrome. J Mol Endocrinol 2017; 59 (01) 93-104
    CrossrefPubMedGoogle Scholar
  • 48 Haoula Z, Ravipati S, Stekel DJ. et al. Lipidomic analysis of plasma samples from women with polycystic ovary syndrome. Metabolomics 2015; 11 (03) 657-666
    CrossrefPubMedGoogle Scholar
  • 49 Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98 (06) E1088-E1096
    CrossrefPubMedGoogle Scholar
  • 50 Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95 (03) 1073-9.e1 , 11
    CrossrefPubMedGoogle Scholar
  • 51 Chen YX, Zhang XJ, Huang J. et al. UHPLC/Q-TOFMS-based plasma metabolomics of polycystic ovary syndrome patients with and without insulin resistance. J Pharm Biomed Anal 2016; 121: 141-150
    CrossrefPubMedGoogle Scholar
  • 52 Jia C, Xu H, Xu Y, Xu Y, Shi Q. Serum metabolomics analysis of patients with polycystic ovary syndrome by mass spectrometry. Mol Reprod Dev 2019; 86 (03) 292-297
    CrossrefPubMedGoogle Scholar
  • 53 Zhao Y, Fu L, Li R. et al. Metabolic profiles characterizing different phenotypes of polycystic ovary syndrome: plasma metabolomics analysis. BMC Med 2012; 10: 153-153
    CrossrefPubMedGoogle Scholar
  • 54 Iwase M, Sonoki K, Sasaki N. et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis 2008; 196 (02) 931-936
    CrossrefPubMedGoogle Scholar
  • 55 Pérez-Chacón G, Astudillo AM, Ruipérez V, Balboa MA, Balsinde J. Signaling role for lysophosphatidylcholine acyltransferase 3 in receptor-regulated arachidonic acid reacylation reactions in human monocytes. J Immunol 2010; 184 (02) 1071-1078
    CrossrefPubMedGoogle Scholar
  • 56 Yea K, Kim J, Yoon JH. et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem 2009; 284 (49) 33833-33840
    CrossrefPubMedGoogle Scholar
  • 57 Barber MN, Risis S, Yang C. et al. Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 2012; 7 (07) e41456
    CrossrefPubMedGoogle Scholar
  • 58 Zhao X, Fritsche J, Wang J. et al. Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 2010; 6 (03) 362-374
    CrossrefPubMedGoogle Scholar
  • 59 Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7: 30
    CrossrefPubMedGoogle Scholar
  • 60 Salehpour S, Nazari L, Hoseini S, Moghaddam PB, Gachkar L. Effects of l–carnitine on polycystic ovary syndrome. JBRA Assist Reprod 2019; 23 (04) 392-395
    PubMedGoogle Scholar
  • 61 Unni SN, Lakshman LR, Vaidyanathan K, Subhakumari KN, Menon NL. Alterations in the levels of plasma amino acids in polycystic ovary syndrome--a pilot study. Indian J Med Res 2015; 142 (05) 549-554
    CrossrefPubMedGoogle Scholar
  • 62 RoyChoudhury S, Mishra BP, Khan T. et al. Serum metabolomics of Indian women with polycystic ovary syndrome using (1)h NMR coupled with a pattern recognition approach. Mol Biosyst 2016; 12: 3407-3416
    CrossrefPubMedGoogle Scholar
  • 63 Huffman KM, Shah SH, Stevens RD. et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009; 32 (09) 1678-1683
    CrossrefPubMedGoogle Scholar
  • 64 Tai ES, Tan ML, Stevens RD. et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 2010; 53 (04) 757-767
    CrossrefPubMedGoogle Scholar
  • 65 Wang TJ, Larson MG, Vasan RS. et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011; 17 (04) 448-453
    CrossrefPubMedGoogle Scholar
  • 66 Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15 (05) 606-614
    CrossrefPubMedGoogle Scholar
  • 67 Irving BA, Carter RE, Soop M. et al. Effect of insulin sensitizer therapy on amino acids and their metabolites. Metabolism 2015; 64 (06) 720-728
    CrossrefPubMedGoogle Scholar
  • 68 Hou E, Zhao Y, Hang J, Qiao J. Metabolomics and correlation network analysis of follicular fluid reveals associations between l-tryptophan, l-tyrosine and polycystic ovary syndrome. Biomed Chromatogr 2020; 35 (03) e4993
    PubMedGoogle Scholar
  • 69 Whigham LD, Butz DE, Dashti H. et al. Metabolic evidence of diminished lipid oxidation in women with polycystic ovary syndrome. Curr Metabolomics 2014; 2 (04) 269-278
    CrossrefPubMedGoogle Scholar
  • 70 Cavalcanti JH, Esteves-Ferreira AA, Quinhones CG. et al. Evolution and functional implications of the tricarboxylic acid cycle as revealed by phylogenetic analysis. Genome Biol Evol 2014; 6 (10) 2830-2848
    CrossrefPubMedGoogle Scholar
  • 71 Sun L, Hu W, Liu Q. et al. Metabonomics reveals plasma metabolic changes and inflammatory marker in polycystic ovary syndrome patients. J Proteome Res 2012; 11 (05) 2937-2946
    CrossrefPubMedGoogle Scholar
  • 72 Webb SJ, Geoghegan TE, Prough RA, Michael Miller KK. The biological actions of dehydroepiandrosterone involves multiple receptors. Drug Metab Rev 2006; 38 (1-2): 89-116
    CrossrefPubMedGoogle Scholar
  • 73 Zhao X, Xu F, Qi B. et al. Serum metabolomics study of polycystic ovary syndrome based on liquid chromatography-mass spectrometry. J Proteome Res 2014; 13 (02) 1101-1111
    CrossrefPubMedGoogle Scholar
  • 74 Buszewska-Forajta M, Rachoń D, Stefaniak A. et al. Identification of the metabolic fingerprints in women with polycystic ovary syndrome using the multiplatform metabolomics technique. J Steroid Biochem Mol Biol 2019; 186: 176-184
    CrossrefPubMedGoogle Scholar
  • 75 Babińska A, Siekierska-Hellmann M, Błaut K. et al. Hormonal activity in clinically silent adrenal incidentalomas. Arch Med Sci 2012; 8 (01) 97-103
    CrossrefPubMedGoogle Scholar
  • 76 Fan X, Jiang J, Huang Z. et al. UPLC/Q-TOF-MS based plasma metabolomics and clinical characteristics of polycystic ovarian syndrome. Mol Med Rep 2019; 19 (01) 280-292
    PubMedGoogle Scholar
  • 77 Reinehr T, Kulle A, Rothermel J. et al. Longitudinal analyses of the steroid metabolome in obese PCOS girls with weight loss. Endocr Connect 2017; 6 (04) 213-224
    CrossrefPubMedGoogle Scholar
  • 78 Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): a hypothesis based on intermediates of energy metabolism. Med Hypotheses 2012; 78 (04) 475-478
    CrossrefPubMedGoogle Scholar
  • 79 Freitas C, Neto AC, Matos L. et al. Follicular fluid redox involvement for ovarian follicle growth. J Ovarian Res 2017; 10 (01) 44
    CrossrefPubMedGoogle Scholar
  • 80 Rice S, Christoforidis N, Gadd C. et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005; 20 (02) 373-381
    CrossrefPubMedGoogle Scholar
  • 81 Sun Z, Chang HM, Wang A. et al. Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry. Reprod Biol Endocrinol 2019; 17 (01) 45
    CrossrefPubMedGoogle Scholar
  • 82 Ma X, Fan L, Meng Y. et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007; 13 (08) 527-535
    CrossrefPubMedGoogle Scholar
  • 83 Matharoo-Ball B, Hughes C, Lancashire L. et al. Characterization of biomarkers in polycystic ovary syndrome (PCOS) using multiple distinct proteomic platforms. J Proteome Res 2007; 6 (08) 3321-3328
    CrossrefPubMedGoogle Scholar
  • 84 Azziz R, Carmina E, Dewailly D. et al; Androgen Excess Society. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91 (11) 4237-4245
    CrossrefPubMedGoogle Scholar
  • 85 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006; 91 (03) 781-785
    CrossrefPubMedGoogle Scholar